Literature DB >> 33772749

Multicomponent behavioral intervention to reduce exposure to anticholinergics in primary care older adults.

Noll L Campbell1,2,3,4,5, Richard J Holden2,3,4,5, Qing Tang6, Malaz A Boustani2,3,4,5, Evgenia Teal7, Jennifer Hillstrom3, Wanzhu Tu2,6, Daniel O Clark2,3,4, Christopher M Callahan2,3,4.   

Abstract

OBJECTIVE: To test the impact of a multicomponent behavioral intervention to reduce the use of high-risk anticholinergic medications in primary care older adults.
DESIGN: Cluster-randomized controlled trial. SETTING AND PARTICIPANTS: Ten primary care clinics within Eskenazi Health in Indianapolis. INTERVENTION: The multicomponent intervention included provider- and patient-focused components. The provider-focused component was computerized decision support alerting of the presence of a high-risk anticholinergic and offering dose- and indication-specific alternatives. The patient-focused component was a story-based video providing education and modeling an interaction with a healthcare provider resulting in a medication change. Alerts within the medical record triggered staff to play the video for a patient. Our design intended for parallel, independent priming of both providers and patients immediately before an outpatient face-to-face interaction. MEASUREMENT: Medication orders were extracted from the electronic medical record system to evaluate the prescribing behavior and population prevalence of anticholinergic users. The intervention was introduced April 1, 2019, through March 31, 2020, and a preintervention observational period of April 1, 2018, through March 31, 2019, facilitated difference in difference comparisons.
RESULTS: A total of 552 older adults had visits at primary care sites during the study period, with mean age of 72.1 (SD 6.4) years and 45.3% African American. Of the 259 provider-focused alerts, only three (1.2%) led to a medication change. Of the 276 staff alerts, 4.7% were confirmed to activate the patient-focused intervention. The intervention resulted in no significant differences in either the number of discontinue orders for anticholinergics (intervention: two additional orders; control: five fewer orders, p = 0.7334) or proportion of the population using anticholinergics following the intervention (preintervention: 6.2% and postintervention: 5.1%, p = 0.6326).
CONCLUSION: This multicomponent intervention did not reduce the use of high-risk anticholinergics in older adults receiving primary care. Improving nudges or a policy-focused component may be necessary to reduce use of high-risk medications.
© 2021 The American Geriatrics Society.

Entities:  

Keywords:  anticholinergic; clinical decision support; deprescribing

Mesh:

Substances:

Year:  2021        PMID: 33772749      PMCID: PMC8959093          DOI: 10.1111/jgs.17121

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   7.538


  39 in total

1.  The medical office of the 21st century (MOXXI): effectiveness of computerized decision-making support in reducing inappropriate prescribing in primary care.

Authors:  Robyn Tamblyn; Allen Huang; Robert Perreault; André Jacques; Denis Roy; James Hanley; Peter McLeod; Réjean Laprise
Journal:  CMAJ       Date:  2003-09-16       Impact factor: 8.262

2.  Prevalence of potentially inappropriate medication use in older adults using the 2012 Beers criteria.

Authors:  Amy J Davidoff; G Edward Miller; Eric M Sarpong; Eunice Yang; Nicole Brandt; Donna M Fick
Journal:  J Am Geriatr Soc       Date:  2015-03-06       Impact factor: 5.562

3.  Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study.

Authors:  Shelly L Gray; Melissa L Anderson; Sascha Dublin; Joseph T Hanlon; Rebecca Hubbard; Rod Walker; Onchee Yu; Paul K Crane; Eric B Larson
Journal:  JAMA Intern Med       Date:  2015-03       Impact factor: 21.873

4.  Understanding older adults' medication decision making and behavior: A study on over-the-counter (OTC) anticholinergic medications.

Authors:  Richard J Holden; Preethi Srinivas; Noll L Campbell; Daniel O Clark; Kunal S Bodke; Youngbok Hong; Malaz A Boustani; Denisha Ferguson; Christopher M Callahan
Journal:  Res Social Adm Pharm       Date:  2018-03-06

5.  Post-ECT confusional states associated with elevated serum anticholinergic levels.

Authors:  F M Mondimore; N Damlouji; M F Folstein; L Tune
Journal:  Am J Psychiatry       Date:  1983-07       Impact factor: 18.112

6.  The anticholinergic risk scale and anticholinergic adverse effects in older persons.

Authors:  James L Rudolph; Marci J Salow; Michael C Angelini; Regina E McGlinchey
Journal:  Arch Intern Med       Date:  2008-03-10

7.  Long-term anticholinergic use and the aging brain.

Authors:  Xueya Cai; Noll Campbell; Babar Khan; Christopher Callahan; Malaz Boustani
Journal:  Alzheimers Dement       Date:  2012-11-22       Impact factor: 21.566

8.  Preventing Alzheimer Disease by Deprescribing Anticholinergic Medications.

Authors:  Noll L Campbell; Richard Holden; Malaz A Boustani
Journal:  JAMA Intern Med       Date:  2019-08-01       Impact factor: 21.873

9.  Temporal trends in anticholinergic medication prescription in older people: repeated cross-sectional analysis of population prescribing data.

Authors:  Deepa Sumukadas; Marion E T McMurdo; Arduino A Mangoni; Bruce Guthrie
Journal:  Age Ageing       Date:  2013-12-10       Impact factor: 10.668

10.  Use of an electronic decision support tool to reduce polypharmacy in elderly people with chronic diseases: cluster randomised controlled trial.

Authors:  Anja Rieckert; David Reeves; Attila Altiner; Eva Drewelow; Aneez Esmail; Maria Flamm; Mark Hann; Tim Johansson; Renate Klaassen-Mielke; Ilkka Kunnamo; Christin Löffler; Giuliano Piccoliori; Christina Sommerauer; Ulrike S Trampisch; Anna Vögele; Adrine Woodham; Andreas Sönnichsen
Journal:  BMJ       Date:  2020-06-18
View more
  2 in total

1.  Reducing anticholinergic medication exposure among older adults using consumer technology: Protocol for a randomized clinical trial.

Authors:  Ephrem Abebe; Noll L Campbell; Daniel O Clark; Wanzhu Tu; Jordan R Hill; Addison B Harrington; Gracen O'Neal; Kimberly S Trowbridge; Christian Vallejo; Ziyi Yang; Na Bo; Alexxus Knight; Khalid A Alamer; Allie Carter; Robin Valenzuela; Philip Adeoye; Malaz A Boustani; Richard J Holden
Journal:  Res Social Adm Pharm       Date:  2020-10-22

2.  Applications of Behavioral Economics to Pharmaceutical Policymaking: A Scoping Review with Implications for Best-Value Biological Medicines.

Authors:  Arnold G Vulto; Isabelle Huys; Yannick Vandenplas; Steven Simoens; Florian Turk
Journal:  Appl Health Econ Health Policy       Date:  2022-08-16       Impact factor: 3.686

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.